The demographic features, clinicopathologic characteristics, treatment outcome and disease-specific prognostic factors of solitary fibrous tumor: a population-based analysis

Alimujiang Wushou1,2, Yi-Zhou Jiang1,2, Yi-Rong Liu1,2 and Zhi-Ming Shao1,2

1 Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Correspondence to: Zhi-Ming Shao, email: zhimingshao@yahoo.com or fd-can@hotmail.com

Keywords: solitary fibrous tumor, SEER analysis

Received: August 09, 2015               Accepted: October 06, 2015               Published: October 19, 2015

ABSTRACT

Background: Solitary fibrous tumor’s (SFT) demographic features, clinicopathologic characteristics, treatment outcome and disease-specific prognostic factors were unexplored comprehensively.

Methods: SEER program was used to identify patients diagnosed with SFT from 1973 to 2012. Overall collected data were analyzed by using the SPSS 18.0.

Results: In total, 804 cases were found including 613 cases with SFT-specific mortality and 801 patients were analyzed for overall survival (OS). The 3-year disease free survival (DFS), 5-year DFS and 10-year DFS were 73.3%, 65.7% and 53.3%. The 3-year OS, 5-year OS and 10-year OS were 71.9%, 63.3% and 47.3%. In the multivariate survival analysis, the age > 51 years (hazard ratio [HR] = 1.851 for DFS, \( P = 0.024 \) and HR = 1.652 for OS, \( P = 0.033 \); Reference [Ref] ≤ 51 years for DFS and ≤ 53 years for OS), SEER stage metastasized tumor (HR = 4.269 for DFS, \( P = 0.000 \) and HR = 2.905 for OS, \( P = 0.028 \), Ref - localized + regional tumor), pathologic grade III + IV (HR = 2.734 for DFS, \( P = 0.001 \) and HR = 2.585 for OS, \( P = 0.000 \), Ref - grade I + II) were adversely associated with DFS and OS. In addition, surgery was favorably associated with DFS (HR = 0.217, \( P = 0.045 \), Ref - surgery + radiotherapy).

Conclusions: The surgery was an independent prognostic factor for DFS. The patient’s age, SEER stage and pathologic grade were SFT-specific independent prognostic indicators for DFS and OS.

INTRODUCTION

Soft tissue sarcomas represent a heterogeneous group of mesenchymal tumors with variable clinical behavior and prognosis [1]. As a result, the treatment modalities of soft tissue sarcoma are increasingly subtype-specific. There are big challenges for the oncologist in treating patients with rare subtypes of soft tissue sarcoma, since adequate instructive data from clinical trials or even coherent studies are not available to guide rigorous evidence-based treatment [2]. Hemangiopericytoma was firstly named by Stout and Murray in 1942. It derives from pericytes around capillaries and postcapillary venules, thus, this tumor can be found in any sites of human body that contain capillaries [3]. The term “hemangiopericytoma” has been retired; tumors diagnosed as hemangiopericytoma in the past are now called solitary fibrous tumor (SFT) [4]. SFT is one of the most commonly misdiagnosed soft tissue sarcomas in clinic because of its unspecified initial clinical presentation. Moreover, accurate pathologic diagnosis of SFT is also a challenge, because up to 15% of all soft tissue sarcomas can have SFT-like pathologic characteristics [5].

Our previous study investigated head and neck (HN) SFTs and found that a treatment protocol emphasizing the surgical removal of the tumor as the first-line treatment, tumor size > 5.0cm, poor pathologic differentiation, deep tumor location and non-surgical treatment were independent adverse prognostic factors for HN SFTs [6, 7].
Currently, only case reports and retrospective series have been reported with relatively small of study population from variety of tumor location. Given the rarity of this tumor, information is still sporadic regarding their unique demographic, clinicopathologic, prognostic and biologic characteristics. Oncologists around the globe have limited management experience, resulting in heterogeneity of treatment paradigms and prognosis.

We speculate that a large nationwide population-based patient cohort may provide an opportunity to evaluate trends in demographic features, clinical presentation, patient characteristics, diagnosis, treatment modalities and prognostic factors of SFT. To better characterize unique demographic features, clinicopathologic characteristics, treatment outcome and prognostic factors of SFT, we carried out a comprehensive analysis of all patients with SFT registered in the Surveillance, Epidemiology, and End Results (SEER) public-access database collected from various geographic areas in the United States from 1973 to 2012.

RESULTS

The demographic and clinicopathologic characteristics of 613 SFT patients with disease-specific survival status

A total of 613 patients with diagnosis of SFT were found in the SEER database with SFT-specific mortality spanning from 1973 to 2012. The median follow-up time was 86.8 (range, 1-478) months. Gender distribution was almost equal between males and females (45.4% and 54.6%, respectively) and a peak incidence occurred during the fifth decade of life. Majority of SFT occurred in white people. About half of the tumors registration came from the Pacific coast. Approximately, one third of SFT cases originated from thoracic, abdominal and pelvic cavity (TAPC) and one-half of SFT cases were classified as SEER stage regional tumor. Surgery was the most common treatment modality and 49.4% of cases were treated with surgery alone. Most of the tumors were pathologically unclassified SFTs and they accounted for nearly 70% of cases. The baseline characteristics of 613 SFT patients are summarized in Table 1.

Disease free survival (DFS) and cox proportional hazards regression analysis

Kaplan-Meier analysis was performed for time-to-event analysis for DFS. The 3-year DFS, 5-year DFS, 10-year DFS, 15-year DFS were 73.3%, 65.7%, 53.3% and 45.9%, respectively. Significant DFS differences were found depending on age (P = 0.000), marital status (P = 0.000), SEER stage (P = 0.006), tumor location (P = 0.000), treatment modality (P = 0.000) and pathologic grade (P = 0.001) (Figure 1). A Cox proportional hazard model was performed to identify prognostic variables for DFS. In the univariate Cox regression analysis, the age > 51 years (P = 0.000; HR = 2.341; ≤ 51 years - as reference [Ref]), SEER stage distant metastasized tumor (P = 0.012; HR = 1.532; localized + regional tumor - as Ref) and pathologic grade III + IV (P = 0.002; HR = 2.210; grade I + II - as Ref) were associated with worse DFS. SFT from TAPC (P = 0.009; HR = 0.412; central nerve system [CNS] - as Ref) and surgery alone (P = 0.000; HR = 0.353; surgery with radiotherapy - as Ref) were associated with favorable DFS. In the multivariate Cox regression analysis, the age (P = 0.024; HR = 1.851; ≤ 51 years - as Ref), SEER stage (P = 0.000; HR = 4.269 for distant metastasized tumor; localized + regional tumor - as Ref), treatment modalities (P = 0.045; HR = 0.217 for surgery alone; surgery + RT - as Ref) and pathologic grade (P = 0.001; HR = 2.734 for grade III + IV; grade I + II - as Ref) were independent prognostic variables for DFS. Details of the Cox proportional hazards regression analysis are shown in Tables 2 and 3.

The demographic and clinicopathologic characteristics of 801 SFT patients with overall survival (OS) status

From 1973 to 2012, there were 804 consecutive registered patients with SFT in the SEER database. Three patients were excluded for survival analysis, due to lack of treatment and follow-up data. The 801 patients included 361 male patients and 440 female patients, with a male-to-female ratio of 0.82 : 1. Their ages ranged from 1 month to 85+ years, with a median of 53 years (Supplementary Figure 1). More than 80% of SFT cases occurred in white people and only 8.8% in black people. Half of the cases came from the Pacific coast, 220 cases from east, 128 cases from the northern plains and 53 cases from southwest. In total, 35.3% of tumors originated from TAPC, 24.5% from CNS, 19.9% from HN region and 16.2% from extremity. According to SEER stage classification, 48.3%, 18.9% and 13.9% patients were classified as localized, regional and distant metastasized SFTs. 87.6% patients treated with surgery included treatment modalities. Only 244 SFT patients had defined pathologic grade data. The median follow-up period was 85.6 (range, 1-478) months. The baseline characteristics of 801 SFT patients with OS status are presented in Table 1.
Figure 1: Disease free survival curves of patients with solitary fibrous tumor compared according to A. age, B. AJCC stage, C. and D. SEER stage, E. and F. pathologic grade, G. and H. treatment modalities. Log-rank test was used to compare curves, and significance (P value) is shown on each panel.
The 3-year OS, 5-year OS, 10-year OS and 15-year OS rates were 71.9%, 63.3%, 47.3% and 38%, respectively. Significant OS differences were identified depending on age ($P = 0.000$), marital status ($P = 0.000$), CHSDA region ($P = 0.006$), tumor location ($P = 0.006$), AJCC stage ($P = 0.003$), SEER stage ($P = 0.027$), treatment modality ($P = 0.000$) and pathologic grade ($P = 0.138$), respectively.
Figure 2: Overall survival curves of patients with solitary fibrous tumor compared according to A. age, B. AJCC stage, C. and D. SEER stage, E. pathologic grade, F. tumor location G. and H. treatment modalities. Log-rank test was used to compare curves, and significance ($P$ value) is shown on each panel.
0.005) (Figure 2 and Supplementary Figure 2). Univariate and multivariate survival analysis utilizing the Cox regression model were performed on the 801 SFT patients. In the univariate Cox regression analysis, the age > 53 years \( (P = 0.000; \text{HR} = 2.253, \leq 53 \text{ years} - \text{as Ref}) \), distant metastasized tumor \( (P = 0.028; \text{HR} = 1.343; \text{localized + regional tumor} - \text{as Ref}) \) and pathologic grade III + IV \( (P = 0.005; \text{HR} = 1.694; \text{Grade I + II} - \text{as Ref}) \) were adversely associated with OS. SFT from TAPC \( (P = 0.007, \text{HR} = 0.493; \text{CNS- as Ref}) \), surgery \( (P = 0.000, \text{HR} = 0.365; \text{RT + surgery} - \text{as Ref}) \) and OCM \( (P = 0.348, \text{HR} = 1.424) \) were favorably associated with OS. The age \( (P = 0.033, \text{HR} = 1.652 \text{ for } > 53 \text{ years}; \leq 53 \text{ years} - \text{as Ref}) \), SEER stage \( (P = 0.005; \text{HR} = 2.585 \text{ for grade III + IV}; \text{grade I + II} - \text{as Ref}) \) were independent prognostic variables for OS (Tables 2 and 3).

**DISCUSSION**

According to the current investigation, incidence rate in gender is almost equal for DFS and slightly higher in female for OS. There is no statistically significant predominance in any gender. In survival analysis, remarkable difference was neither identified in DFS, nor in OS \( (P = 0.786 \text{ and } P = 0.833, \text{respectively, Supplementary Figure 2}) \). In most of the previously published case series, the typical age at presentation ranged from the third to the

| Parameters          | DFS            | OS            |
|---------------------|----------------|---------------|
|                     | HR (95% CI)    | P-value       | HR (95% CI)    | P-value       |
| Gender              |                |               |                |               |
| Female              | 1.00 Reference | 0.786         | 1.00 Reference | 0.834         |
| Male                | 1.034 (0.813-1.315) | 0.980 (0.809-1.186) |
| Age                 |                |               |                |               |
| ≤ 51 years          | 1.00 Reference | 0.000         | 1.00 Reference | 0.000         |
| > 51 years          | 2.341 (1.829-2.996) | 2.253 (1.850-2.742) |
| Race                |                |               |                |               |
| White               | 1.00 Reference | 0.000         | 1.00 Reference | 0.000         |
| Black               | 1.353 (0.888-2.061) | 1.430 (0.985-2.075) | 0.060         |
| Others              | 1.317 (0.721-2.406) | 1.662 (1.026-2.691) | 0.039         |
| Marital status      |                |               |                |               |
| Married             | 1.00 Reference | 0.964         | 1.00 Reference | 0.626         |
| Other status        | 1.006 (0.970-1.280) | 1.049 (0.867-1.269) | 0.626         |
| CHSDA Region        |                |               |                |               |
| East                | 1.00 Reference | 0.000         | 1.00 Reference | 0.015         |
| Northern plain      | 0.411 (0.258-0.654) | 0.628 (0.431-0.914) | 0.007         |
| Pacific coast       | 0.925 (0.589-1.453) | 0.996 (0.687-1.445) | 0.985         |
| Southwest           | 0.570 (0.376-0.864) | 0.761 (0.540-1.073) | 0.119         |
| Locations           |                |               |                |               |
| Central nerve system | 1.00 Reference | 0.050         | 1.00 Reference | 0.031         |
| Head and neck       | 0.537 (0.288-1.001) | 0.579 (0.353-0.950) | 0.007         |
| TAPC                | 0.412 (0.213-0.798) | 0.493 (0.296-0.822) | 0.007         |
| Extremity           | 0.789 (0.434-1.435) | 0.755 (0.470-1.215) | 0.248         |
| Other location      | 0.800 (0.429-1.493) | 0.696 (0.420-1.154) | 0.160         |
| AJCC Stage          |                |               |                |               |
| Stage I + II        | 1.00 Reference | 0.271         | 1.00 Reference | 0.182         |
| Stage III + IV      | 11.035 (0.024-549.7) | 0.010 (0.000-8.658) | 0.160         |
| SEER stage          |                |               |                |               |
| Localized + regional| 1.00 Reference | 0.012         | 1.00 Reference | 0.028         |
| Distant metastasized| 1.532 (1.100-2.134) | 1.343 (1.032-1.749) | 0.505         |
| Treatment           |                |               |                |               |
| Radiotherapy + surgery | 1.00 Reference | 0.047         | 0.450 (0.252-0.803) | 0.007         |
| Surgery + radiotherapy | 0.489 (0.242-0.992) | 0.365 (0.261-0.508) | 0.000         |
| Surgery alone       | 0.353 (0.237-0.526) | 0.333 (0.244-0.454) | 0.000         |
| Radiotherapy alone  | 0.294 (0.200-0.431) | 0.751 (0.454-1.242) | 0.264         |
| OCM                 | 0.742 (0.398-1.384) | 0.348         | 0.169         | 0.361 (0.130-1.000) | 0.050         |
| Unknown             | 0.436 (0.134-1.422) | 0.169         | 0.361 (0.130-1.000) | 0.050         |
| Treatment           |                |               |                |               |
| Surgery with radiotherapy | 1.00 Reference | 0.021         | 1.00 Reference | 0.053         |
| Surgery alone       | 0.738(0.570-0.955) | 1.226 (0.997-1.506) | 0.005         |
| Pathologic grade    |                |               |                |               |
| Grade I + II        | 1.00 Reference | 0.002         | 1.00 Reference | 0.005         |
| Grade III + IV      | 2.210 (1.338-3.649) | 1.694 (1.169-2.455) | 0.005         |

**Abbreviations:** SEER, surveillance, epidemiology, and end results; SFT, solitary fibrous tumor; DFS, disease free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CHSDA, contract health service delivery areas; TAPC, thoracic, abdominal and pelvic cavity; OCM, Others combined modalities; AJCC, american joint committee on cancer.
fifth decades [8-10]. In this series, SFT most frequently occurs during the fifth decades of life (Supplementary Figure 2). The majority of investigation about SFT are based on single-center experience and mostly include no more than 30–50 cases. Given their small sample size, those investigations are often not sufficiently powerful to detect small differences in survival analysis according to common demographic factors such as age, gender and race. In our current investigation, patient’s age, gender and race were analyzed as categorical variables in both univariate and multivariate survival analyses. The results demonstrate that apart from the age, no survival difference in DFS or OS was found to be associated with race or gender (Table 2 and Supplementary Figure 2).

Up to date, more than two thousand studies are available about SFT in the PubMed. SFT is reported from a variety of tumor locations. In accordance with previous reports, SFT occurred at any age-period and any site of the body in present series (Supplementary Figure 1). To better characterize, we categorized the tumor location into five groups (CNS, HN, TAPC, extremity and other location), although there are many other possibilities to categorize the tumor location. In this categorization, significant survival differences were found, where HN and TAPC SFTs were favorably associated with DFS (Ref - CNS) in univariate survival analysis. However, tumor location was not an independent prognostic indicator in multivariate survival analysis. In this categorization, significant survival differences were found, where HN and TAPC SFTs were favorably associated with DFS (Ref - CNS) in univariate survival analysis. However, tumor location was not an independent prognostic indicator in multivariate survival analysis. Nevertheless, detailed SEER stage data was available in this study and it was an independent prognostic indicator not only for DFS but also for OS.

Whether the SFT patients can benefit from RT is a most widely investigated hot topic, especially in the CNS SFTs [13-17]. One of the main interests of this study is to hopefully confirm the role of RT in SFT treatment. The RT for SFT has been widely used alone or combined with surgery as part of the management algorithm for several decades. Until now, the role of RT in SFT treatment is still controversial. Lately, investigators analyzed 227 CNS SFT cases in the SEER database during the years of 2000-2009 and confirmed a survival benefit for patients treated with surgery in combination with adjuvant RT, while the effect was not appreciated with surgery alone. In another series, investigators found that treatment protocol of combined adjuvant RT with surgery seemed to hinder tumor progression, but had no effect on OS [18]. The addition of adjuvant RT to surgery improved the local recurrence, but did not increase overall survival of patients with AJCC stage III + IV. The small number of patients with AJCC stage in the Cox model did not permit a multivariate survival analysis for independent prognostic factor. In our previous report, we also failed to perform the AJCC stage in multivariate survival analysis of HN SFT due to the incomplete staging data. As far as we know, there aren’t any report regarding TNM/AJCC stage identified as an independent prognostic variable for SFT. Nevertheless, detailed SEER stage data was available in this study and it was an independent prognostic indicator not only for DFS but also for OS.

| Parameters       | DFS (95% CI) | P-value | OS (95% CI) | P-value |
|------------------|-------------|---------|-------------|---------|
| **Age**          |             |         |             |         |
| ≤ 51 years       | 1.00 Reference | 0.024   | 1.00 Reference | 0.033   |
| > 51 years       | 1.851 (1.083-3.165) |         | 1.652 (1.042-2.618) |         |
| **SEER stage**   |             |         |             |         |
| Localized + regional | 1.00 Reference | 0.000   | 1.00 Reference | 0.028   |
| Metastasized     | 4.269 (2.144-8.499) |         | 2.905 (1.673-5.043) |         |
| **Treatment modalities** |         |         |             |         |
| Radiotherapy + surgery | 1.00 Reference |         | 1.00 Reference |         |
| Surgery + radiotherapy | 0.493 (0.129-0.719) | 0.412   | 0.880 (0.170-4.572) | 0.879   |
| Surgery alone     | 0.217 (0.156-0.747) | 0.045   | 0.811 (0.158-2.634) | 0.476   |
| Radiotherapy alone | 0.229 (0.375-2.994) | 0.055   | 0.586 (0.154-2.225) | 0.432   |
| **Pathologic grade** |         |         |             |         |
| Grade I + II     | 1.00 Reference | 0.001   | 1.00 Reference | 0.000   |
| Grade III + IV   | 2.734 (1.517-4.925) |         | 2.585 (1.556-4.284) |         |

**Abbreviations:** DFS, disease free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; SEER, surveillance, epidemiology, and end results.
common adverse prognostic factors after surgery such as high pathologic grade and unconfirmed surgical margins [6, 7, 10]. As retrospective study, it is almost impossible to make a standard survival comparison between patients treated with surgery alone and surgery with RT. Because those patients did not even have similar TNM/AJCC stage. Therefore, it is difficult to draw a firm conclusion that SFT patients cannot benefit from RT. Multi-center prospective controlled clinical studies are necessary to further confirm the role of RT in SFT treatment.

We acknowledge the limitations that come with our investigation. In the SEER database, data on important factors such as TNM/AJCC stage and pathologic grade are incomplete. Establishment of the role of chemotherapy is another important issue. A notable limitation of the SEER database is that there is no chemotherapy information available for analysis. In addition, not all patients have complete information.

CONCLUSIONS

In summary, to the best of our knowledge, the present comprehensive analysis of the overall 804 cases from SEER database is the first of its kind to clearly define the demographic features, clinicopathologic characteristics, treatment outcome and prognostic factors of patients with SFT, and is also the largest SFT series to date. Despite the above limitations, for the first time we found that the age > 51 years (Ref- ≤ 51 years, ≤ 53 years for OS), SEER stage distant metastasized tumor (Ref- localized + regional tumor) and high pathologic grade III + IV (Ref- Grade I + II) were independent adverse prognostic indicators for DFS and OS. Regarding the treatment, the surgery was an independent favorable prognosis factor for DFS (Ref- RT + surgery).

MATERIALS AND METHODS

Date extraction

SEER*Stat software from the National Cancer Institute (Surveillance Research Program, National Cancer Institute SEER*Stat software, http://www.seer.cancer.gov/seerstat, Version 8.2.1) was applied for data extraction. International Classification of Diseases for Oncology (ICD-O-3) codes for hemangiopericytoma (9150) was used for identification of cases with a diagnosis of SFT registered in the SEER database.

Variable selection and statistical analysis

The study variables included gender, age, race, marital status, contract health service delivery areas (CHSDA) region, primary tumor location, SEER stage, American joint committee on cancer (AJCC) stage, pathologic grade, treatment modalities, follow-up time and outcome status. Not all of the cases that we identified contained all these data. Collected data were analyzed using the software of the Statistical Package for Social Sciences, version 18.0, for Windows (SPSS, Chicago, IL). Differences in the numerical variables were assessed using the Student’s t test or non-parametric Wilcoxon test. The chi square test or Fisher exact test for categorical variables was used for two group comparisons of parameters. The survival curves were generated using the Kaplan-Meier method, and the log-rank test was performed to evaluate the survival difference. Adjusted hazard ratios (HRs) along with 95% confidence intervals (CIs) were calculated using the Cox proportional hazards regression model. When the P value was < 0.05, the difference was regarded as statistically significant. All statistical tests were two tailed.

ACKNOWLEDGMENTS

The authors thank Kamila Abulimiti (MD) from Strayer University (USA) for her editorial help.

FUNDING

This study was supported by Project Funded by China Postdoctoral Science Foundation (2015M571493).

CONFLICTS OF INTEREST

The authors made no disclosures.

REFERENCES

1. Canter RJ, Beal S, Borys D, Martinez SR, Bold RJ and Robbins AS. Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. J Am Coll Surg. 2010; 210:191-198. e192.
2. Aufforth RD, Baker JJ and Hong JK. Soft Tissue Sarcoma. Surgical Oncology. 2015.
3. Stout AP and Murray MR. Hemangiopericytoma A Vascular Tumor Featuring Zimmermann’s Pericytes. Ann Surg. 1942; 116:26-33.
4. Brooks JS and Lee S. Contemporary diagnostics: sarcoma pathology update. J Surg Oncol. 2015; 111:513-519.
5. Fletcher CDM. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006; 48.
6. Wushou A, Bai XF, Qi H, Xu Z, Zheng J and Li G. Haemangiopericytoma of the jaw. J Craniomaxillofac Surg. 2014; 42:689-694.
7. Wushou A, Miao XC and Shao ZM. Treatment outcome and prognostic factors of head and neck hemangiopericytoma: A meta-analysis. Head Neck. 2015; 37:1685-90.
8. Enzinger FM and Smith BH. Hemangiopericytoma. An analysis of 106 cases. Hum Pathol. 1976; 7(1).
9. Mena H, Ribas JL, Pezeshkpour GH, Cowan DN and Parisi JE. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol. 1991; 22:84-91.
10. Espat NJ, Lewis JJ, Leung D, Woodruff JM, Antonescu CR, Shia J and Brennan MF. Conventional hemangiopericytoma. Cancer. 2002; 95:1746-1751.
11. Hall WA, Ali AN, Gullett N, Crocker I, Landry JC, Shu HK, Prabhu R and W C. Comparing central nervous system (CNS) and extra-CNS hemangiopericytomas in the Surveillance, Epidemiology, and End Results program: analysis of 655 patients and review of current literature. Cancer. 2012; 118:5331-5338.
12. Lahat G, Tuvin D, Wei C, Anaya DA, Bekele BN, Lazar AJ, Pisters PW, Lev D and Pollock RE. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol. 2008; 15:2739-2748.
13. Soyuer S, Chang EL, Selek U, McCutcheon IE and Maor MH. Intracranial meningeal hemangiopericytoma: the role of radiotherapy. Cancer. 2004; 100:1491-1497.
14. Dufour H, Métellus P, Fuentes S, Murracciole X, Régis J, Figarella-Branger D and Grisoli F. Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery. 2001; 48:756-763.
15. Combs SE, Thilmann C, Debus J and Schulz-Ertner D. Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer. 2005; 104:2457-2465.
16. Chang SD and Sakamoto GT. The role of radiosurgery for hemangiopericytomas. Neurosurg Focus. 2003; 14:1-5.
17. Sonabend AM, Zacharia BE, Goldstein H, Bruce SS, Hershman D, Neugut AI and Bruce JN. The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis: Clinical article. J Neurosurg. 2014; 120:300-308.
18. Melone AG, D’Elia A, Santoro F, Salvati M, Delfini R, Cantore G and Santoro A. Intracranial hemangiopericytoma—our experience in 30 years: a series of 43 cases and review of the literature. World Neurosurg. 2014; 81:556-562.
19. Duval M, Hwang E and Kilty SJ. Systematic review of treatment and prognosis of sinonasal hemangiopericytoma. Head Neck. 2013; 35:1205-1210.